Anti-C5A Binding Moieties with High Blocking Activity
AssigneeInflaRx GmbH
InventorsRenfeng Guo, Niels Christoph Reidemann, Yan Li, Beifen Shen
Life of this patent
Estimating the term…
Loading patent…
AssigneeInflaRx GmbH
InventorsRenfeng Guo, Niels Christoph Reidemann, Yan Li, Beifen Shen
Estimating the term…
The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention of various acute and chronic diseases, in particular acute inflammatory diseases, such as the systemic inflammatory response syndrome (SIRS), and different degrees of sepsis including sepsis, severe sepsis, and septic shock.
A binding moiety which binds to a conformational epitope formed by amino acid sequences X1X2ETCEX3RX4 (SEQ ID NO:
8-11. (canceled)
An antibody or an antigen-binding fragment thereof comprising:
An antibody or an antigen-binding fragment thereof comprising:
An antibody or an antigen-binding fragment thereof comprising a set of heavy chain CDR3, heavy chain CDR2, and heavy chain CDR1 sequences selected from one of the following sets:
An antibody or an antigen-binding fragment thereof comprising a set of light chain CDR3, light chain CDR2, and light chain CDR1 sequences selected from one of the following sets:
(canceled)
Dependencies are inferred from the claim text.